Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Synovial Sarcoma, Soft Tissue Sarcoma
- Main trialPhase 1
- “This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic therapy; have relapsed/refractory tumors; have unresectable or metastatic disease; and are not candidates for available therapies known to confer clinical benefit. The study will characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of CFT8634.”In the company’s words, NCT05355753 on ClinicalTrials.gov
Other drugs for Synovial Sarcoma
- AL3818Advenchen Laboratories, LLC · Phase 3
- TBI-1301Takara Bio Inc. · Phase 3
- Letetresgene autoleucelUSWM CT, LLC · GSK · Phase 2
- MASCT-IHRYZ Biotech Co. · Phase 2
- PeptiCRAd-1Valo Therapeutics Oy · Phase 1
- CLR 131Cellectar Biosciences, Inc. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Terminated | 19 Dec 2023 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026